Biology of the TAM receptors

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 11, 2013, Pages

  Lemke, Greg ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXL RECEPTOR TYROSINE KINASE; LIGAND; MERTK PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; TYRO3 PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; AUTOIMMUNE DISEASE; CELL MEMBRANE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NEOPLASM; PHAGOCYTOSIS; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION;

ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; CELL MEMBRANE; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; NEOPLASMS; PHAGOCYTOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; VIRUS DISEASES;

EID: 84882311715     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a009076     Document Type: Article

References (178)

1. Gonzalez A-N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, Deniz J, Ramirez C, Diaz M, Gallardo G, et al. 2009. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31: 245-258.
2. Ait-Oufella H, Pouresmail V, Simon T, Blanc-Brude O, Kinugawa K, Merval R, Offenstadt G, Leseche G, Cohen PL, Tedgui A, et al. 2008. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol 28: 1429-1431.
3. Akira S. 2006. TLR signaling. Curr Top Microbiol Immunol 311: 1-16.
4. Allen MP, Linseman DA, Udo H, Xu M, Schaack JB, Varnum B, Kandel ER, Heidenreich KA, Wierman ME. 2002a. Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase. Mol Cell Biol 22: 599-613.
5. Allen MP, Xu M, Linseman DA, Pawlowski JE, Bokoch GM, Heidenreich KA, Wierman ME. 2002b. Adhesion-related kinase repression of gonadotropin-releasing hormone gene expression requires Rac activation of the extracellular signal-regulated kinase pathway. J Biol Chem 277: 38133-38140.
6. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, Arnout J, Dewerchin M, Hoylaerts M, Herbert J, et al. 2001. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 7: 215-221.
7. Angelillo-Scherrer A, Burnier L, Flores N, Savi P, DeMol M, Schaeffer P, Herbert J-M, Lemke G, Goff SP, Matsushima GK, et al. 2005. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest 115: 237-246.
8. Arman E, Haffner-Krausz R, Chen Y, Heath JK, Lonai P. 1998. Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. Proc Natl Acad Sci 95: 5082-5087.
9. Bandyopadhyay PK. 2008. Vitamin K-dependent g-glutamylcarboxylation: An ancient posttranslational modification. Vitam Horm 78: 157-184.
10. Berclaz G, Altermatt HJ, Rohrbach V, Kieffer I, Dreher E, Andres AC. 2001. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol 12: 819-824.
11. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X, Hoebe K. 2006. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 24: 353-389.
12. Bonjardim CA, Ferreira PC, Kroon EG. 2009. Interferons: Signaling, antiviral and viral evasion. Immunol Lett 122: 1-11.
13. Bourne MC, Campbell DA, Tansley K. 1938. Hereditary degeneration of the rat retina. Br J Ophthalmol 22: 613-623.
14. Braunger J, Schleithoff L, Schulz AS, Kessler H, Lammers R, Ullrich A, Bartram CR, Janssen JW. 1997. Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene 14: 2619-2631.
15. Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J. 2004. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 104: 143-148.
16. Burstyn-Cohen T, Heeb MJ, Lemke G. 2009. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Invest 119: 2942-2953.
17. Burstyn-Cohen T, Lew ED, Través PG, Burrola PG, Hash JC, Lemke G. 2012. Genetic dissection of TAM receptor-ligand interaction in retinal pigment epithelial cell phagocytosis. Neuron 76: 1123-1132.
18. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al. 2013. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19: 279-290.
19. Cakal B, Gokmen A, Yalinkilic M, Cakal E, Ayaz S, Nadir I, Ozin Y, Dagli U, Ulker A. 2010. Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease. Blood Coagul Fibrinolysis 21: 118-121.
20. Callahan MK, Popernack PM, Tsutsui S, Truong L, Schlegel RA, Henderson AJ. 2003. Phosphatidylserine on HIV envelope is a cofactor for infection of monocytic cells. J Immunol 170: 4840-4845.
21. Camenisch TD, Koller BH, Earp HS, Matsushima GK. 1999. A novel receptor tyrosine kinase, Mer, inhibits TNF-a production and lipopolysaccharide-induced endotoxic shock. J Immunol 162: 3498-3503.
22. Cavet ME, Smolock EM, Ozturk OH, World C, Pang J, Konishi A, Berk BC. 2008. Gas6-Axl receptor signaling is regulated by glucose in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 28: 886-891.
23. Chen J, Carey K, Godowski PJ. 1997. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 14: 2033-2039.
24. Chen Y, Wang H, Qi N, Wu H, Xiong W, Ma J, Lu Q, Han D. 2009. Functions of TAM RTKs in regulating spermatogenesis and male fertility in mice. Reproduction 138: 655-666.
25. Cheong HS, Lee SO, Choi CB, Sung YK, Shin HD, Bae SC. 2007. MERTK polymorphisms associated with risk of haematological disorders among Korean SLE patients. Rheumatology (Oxford) 46: 209-214.
26. Coleman JA, Kwok MC, Molday RS. 2009. Localization, purification, and functional reconstitution of the P4-ATPase Atp8a2, a phosphatidylserine flippase in photoreceptor disc membranes. J Biol Chem 284: 32670-32679.
27. Collett GD, Sage AP, Kirton JP, Alexander MY, Gilmore AP, Canfield AE. 2007. Axl/phosphatidylinositol 3-kinase signaling inhibits mineral deposition by vascular smooth muscle cells. Circ Res 100: 502-509.
28. Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava S, Varnum B, Liu ET, Cance WG. 1995. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 60: 791-797.
29. Croker BA, Kiu H, Nicholson SE. 2008. SOCS regulation of the JAK/STATsignalling pathway. Semin Cell Dev Biol 19: 414-422.
30. Crosier PS, Lewis PM, Hall LR, Vitas MR, Morris CM, Beier DR, Wood CR, Crosier KE. 1994. Isolation of a receptor tyrosine kinase (DTK) from embryonic stem cells: Structure, genetic mapping and analysis of expression. Growth Factors 11: 125-136.
31. Dahlback B. 2000. Blood coagulation. Lancet 355: 1627-1632.
32. Dai W, Pan H, Hassanain H, Gupta SL, Murphy MJ Jr. 1994. Molecular cloning of a novel receptor tyrosine kinase, tif, highly expressed in human ovary and testis. Oncogene 9: 975-979.
33. D'Cruz PM, Yasumura D, Weir J, Matthes MT, Abderrahim H, LaVail MM, Vollrath D. 2000. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum Mol Genet 9: 645-651.
34. Diakou M, Kostadima V, Giannopoulos S, Zikou AK, Argyropoulou MI, Kyritsis AP. 2011. Cerebral venous thrombosis in an adolescent with ulcerative colitis. Brain Dev 33: 49-51.
35. Diamond MS. 2003. Evasion of innate and adaptive immunity by flaviviruses. Immunol Cell Biol 81: 196-206.
36. Duncan HJ, LaVail MM, Yasumura D, Matthes MT, Yang H, Trautmann N, Chappelow AV, Feng W, Earp HS, Matsushima GK, et al. 2003. An RCS-like retinal dystrophy phenotype in mer knockout mice. Invest Ophthalmol Visual Sci 44: 826-838.
37. Edwards RB, Szamier RB. 1977. Defective phagocytosis of isolated rod outer segments by RCS rat retinal pigment epithelium in culture. Science 197: 1001-1003.
38. Ekman C, Stenhoff J, Dahlback B. 2010. Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. J Thromb Haemost 8: 838-844.
39. Elliott MR, Ravichandran KS. 2010. Clearance of apoptotic cells: Implications in health and disease. J Cell Biol 189: 1059-1070.
40. Evenas P, Dahlback B, Garcia de Frutos P. 2000. The first laminin G-type domain in the SHBG-like region of protein S contains residues essential for activation of the receptor tyrosine kinase sky. Biol Chem 381: 199-209.
41. Feng W, Yasumura D, Matthes MT, LaVail MM, Vollrath D. 2002. Mertk triggers uptake of photoreceptor outer segments during phagocytosis by cultured retinal pigment epithelial cells. J Biol Chem 277: 17016-17022.
42. Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, Spizz G, Varnum B, Der C, Liu ET. 1996. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol 16: 135-145.
43. Fridell YW, Villa J Jr, Attar EC, Liu ET. 1998. GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem 273: 7123-7126.
44. Fujimoto J, Yamamoto T. 1994. brt, a mouse gene encoding a novel receptor-type protein-tyrosine kinase, is preferentially expressed in the brain. Oncogene 9: 693-698.
45. Gaipl US, Munoz LE, Grossmayer G, Lauber K, Franz S, Sarter K, Voll RE, Winkler T, Kuhn A, Kalden J, et al. 2007. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 28: 114-121.
46. Gal A, Li Y, Thompson DA, Weir J, Orth U, Jacobson SG, Apfelstedt-Sylla E, Vollrath D. 2000. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet 26: 270-271.
47. Gasic GP, Arenas CP, Gasic TB, Gasic GJ. 1992. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci 89: 2317-2320.
48. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G. 1995. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378: 390-394.
49. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, et al. 2012. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 13: 1118-1128.
50. Georgescu MM, Kirsch KH, Shishido T, Zong C, Hanafusa H. 1999. Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kB. Mol Cell Biol 19: 1171-1181.
51. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, et al. 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci 107: 1124-1129.
52. Goruppi S, Ruaro E, Varnum B, Schneider C. 1997. Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol 17: 4442-4453.
53. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. 1994. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 5: 647-657.
54. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, et al. 2006. Ectopic expression of the protooncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res 12: 2662-2669.
55. Grommes C, Lee CY, Wilkinson BL, Jiang Q, Koenigsknecht-Talboo JL, Varnum B, Landreth GE. 2008. Regulation of microglial phagocytosis and inflammatory gene expression by Gas6 acting on the Axl/Mer family of tyrosine kinases. J Neuroimmune Pharmacol 3: 130-140.
56. He L, Zhang J, Jiang L, Jin C, Zhao Y, Yang G, Jia L. 2010. Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis. Mol Carcinog 49: 882-891.
57. Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, et al. 2010. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 10: 1009-1018.
58. Heiring C, Dahlback B, Muller YA. 2004. Ligand recognition and homophilic interactions in Tyro3: Structural insights into the Axl/Tyro3 receptor tyrosine kinase family. J Biol Chem 279: 6952-6958.
59. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, et al. 2010. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70: 1544-1554.
60. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE. 2008. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 268: 314-324.
61. Huang M, Rigby AC, Morelli X, Grant MA, Huang G, Furie B, Seaton B, Furie BC. 2003. Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat Struct Biol 10: 751-756.
62. Huang X, Finerty P Jr, Walker JR, Butler-Cole C, Vedadi M, Schapira M, Parker SA, Turk BE, Thompson DA, Dhe-Paganon S. 2009. Structural insights into the inhibited states of the Mer receptor tyrosine kinase. J Struct Biol 165: 88-96.
63. Hurtado B, Munoz X, Recarte-Pelz P, Garcia N, Luque A, Krupinski J, Sala N, Garcia de Frutos P. 2011. Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAMreceptor tyrosine kinases in human atherosclerotic carotid plaques. Thromb Haemost 105: 873-882.
64. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, Muigg A, et al. 2008. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 14: 130-138.
65. Ishimoto Y, Ohashi K, Mizuno K, Nakano T. 2000. Promotion of the uptake of PS liposomes and apoptotic cells by a product of growth arrest-specific gene, gas6. J Biochem 127: 411-417.
66. Iwasaki A, Medzhitov R. 2004. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995.
67. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros PF, Bartram CR. 1991. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6: 2113-2120.
68. Jia R, Hanafusa H. 1994. The proto-oncogene of v-eyk (v-ryk) is a novel receptor-type protein tyrosine kinase with extracellular Ig/GN-III domains. J Biol Chem 269: 1839-1844.
69. Jia R, Mayer BJ, Hanafusa T, Hanafusa H. 1992. A novel oncogene, v-ryk, encoding a truncated receptor tyrosine kinase is transduced into the RPL30 virus without loss of viral sequences. J Virol 66: 5975-5987.
70. Kawasaki Y, Nakagawa A, Nagaosa K, Shiratsuchi A, Nakanishi Y. 2002. Phosphatidylserine binding of class B scavenger receptor type I, a phagocytosis receptor of testicular sertoli cells. J Biol Chem 277: 27559-27566.
71. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, et al. 2010. Inhibition ofMer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 9: 1298-1307.
72. Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H, Maitra A. 2009. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8: 618-626.
73. Kulman JD, Harris JE, Nakazawa N, Ogasawara M, Satake M, Davie EW. 2006. Vitamin K-dependent proteins in Ciona intestinalis, a basal chordate lacking a blood coagulation cascade. Proc Natl Acad Sci 103: 15794-15799.
74. Lai C, Lemke G. 1991. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 6: 691-704.
75. Lai C, Gore M, Lemke G. 1994. Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene 9: 2567-2578.
76. Lan Z, Wu H, Li W, Wu S, Lu L, Xu M, Dai W. 2000. Transforming activity of receptor tyrosine kinase Tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway. Blood 95: 633-638.
77. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. 1995. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378: 394-398.
78. Lemke G, Burstyn-Cohen T. 2010. TAM receptors and the clearance of apoptotic cells. Ann NY Acad Sci 1209: 23-29.
79. Lemke G, Rothlin CV. 2008. Immunobiology of the TAM receptors. Nat Rev Immunol 8: 327-336.
80. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. 2004. Identification of the gene for vitamin K epoxide reductase. Nature 427: 541-544.
81. Lijnen HR, Christiaens V, Scroyen L. 2011. Growth arrestspecific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J Pharmacol Exp Ther 337: 457-464.
82. Ling L, Kung HJ. 1995. Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol Cell Biol 15: 6582-6592.
83. Ling L, Templeton D, Kung HJ. 1996. Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase. J Biol Chem 271: 18355-18362.
84. Linger RM, Keating AK, Earp HS, Graham DK. 2008. TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100: 35-83.
85. Liu Y, Cousin JM, Hughes J, Van Damme J, Seckl JR, Haslett C, Dransfield I, Savill J, Rossi AG. 1999. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol 162: 3639-3646.
86. Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, et al. 2012. Discovery of novel small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia. ACS Med Chem Lett 3: 129-134.
87. Lu Q, Lemke G. 2001. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293: 306-311.
88. Lu Q, Gore M, Zhang Q, Camenisch T, Boast S, Casagranda F, Lai C, Skinner MK, Klein R, Matsushima GK, et al. 1999. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398: 723-728.
89. Ma GZ, Stankovich J, Kilpatrick TJ, Binder MD, Field J. 2011. Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility. PLoS ONE 6: e16964.
90. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, et al. 2007. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26: 3909-3919.
91. Mahajan NP, Earp HS. 2003. An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1 and the Mer receptor tyrosine kinase: A mechanism for localizing guanine nucleotide-exchange factor action. J Biol Chem 278: 42596-42603.
92. Manfioletti G, Brancolini C, Avanzi G, Schneider C. 1993. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 13: 4976-4985.
93. Manning G, Plowman GD, Hunter T, Sudarsanam S. 2002a. Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci 27: 514-520.
94. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002b. The protein kinase complement of the human genome. Science 298: 1912-1934.
95. Mark MR, Scadden DT, Wang Z, Gu Q, Goddard A, Godowski PJ. 1994. rse, a novel receptor-type tyrosine kinase with homology to Axl/Ufo, is expressed at high levels in the brain. J Biol Chem 269: 10720-10728.
96. Mark MR, Chen J, Hammonds RG, Sadick M, Godowsk PJ. 1996. Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem 271: 9785-9789.
97. Marshak-Rothstein A. 2006. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6: 823-835.
98. McColl A, Bournazos S, Franz S, Perretti M, Morgan BP, Haslett C, Dransfield I. 2009. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol 183: 2167-2175.
99. Meertens L, Carnec X, Lecoin MP, Ramdasi R, Guivel-Benhassine F, Lew E, Lemke G, Schwartz O, Amara A. 2012. The TIM and TAMfamilies of phosphatidylserine receptors mediate Dengue virus entry. Cell Host Microbe 12: 544-557.
100. Meesters EW, Hansen H, Spronk HM, Hamulyak K, Rosing J, Rowshani AT, ten Berge IJ, ten Cate H. 2007. The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul Fibrinolysis 18: 21-28.
101. Melaragno MG, Wuthrich DA, Poppa V, Gill D, Lindner V, Berk BC, Corson MA. 1998. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circ Res 83: 697-704.
102. Melaragno MG, Fridell YW, Berk BC. 1999. The Gas6/Axl system: A novel regulator of vascular cell function. Trends Cardiovasc Med 9: 250-253.
103. Mercer J. 2011. Viral apoptotic mimicry party: P. S. Bring your own Gas6. Cell Host Microbe 9: 255-257.
104. Mercer J, Helenius A. 2008. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320: 531-535.
105. Mercer J, Helenius A. 2010. Apoptotic mimicry: Phosphatidylserine-mediated macropinocytosis of vaccinia virus. Ann NY Acad Sci 1209: 49-55.
106. Ming Cao W, Murao K, Imachi H, Sato M, Nakano T, Kodama T, Sasaguri Y, Wong NC, Takahara J, Ishida T. 2001. Phosphatidylinositol 3-OH kinase-Akt/protein kinase B pathway mediates Gas6 induction of scavenger receptor A in immortalized humanvascular smooth muscle cell line. Arterioscler Thromb Vasc Biol 21: 1592-1597.
107. Morizono K, Xie Y, Olafsen T, Lee B, Dasgupta A, Wu AM, Chen IS. 2011. The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe 9: 286-298.
108. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, Mizuno K. 1996. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 271: 30022-30027.
109. Nagata S, Hanayama R, Kawane K. 2010. Autoimmunity and the clearance of dead cells. Cell 140: 619-630.
110. Nandrot EF, Dufour EM. 2010. Mertk in daily retinal phagocytosis: A history in the making. Adv Exp Med Biol 664: 133-140.
111. Nielsen-Preiss SM, Allen MP, Xu M, Linseman DA, Pawlowski JE, Bouchard RJ, Varnum BC, Heidenreich KA, Wierman ME. 2007. Adhesion-related kinase induction of migration requires phosphatidylinositol-3-kinase and Ras stimulation of Rac activity in immortalized gonadotropin-releasing hormone neuronal cells. Endocrinology 148: 2806-2814.
112. Nyberg P, He X, Hardig Y, Dahlback B, Garcia de Frutos P. 1997. Stimulation of Sky tyrosine phosphorylation by bovine protein S-domains involved in the receptor-ligand interaction. Eur J Biochem 246: 147-154.
113. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R III, Le Beau MM, Earp HS, Liu ET. 1991. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11: 5016-5031.
114. Ohashi K, Mizuno K, Kuma K, Miyata T, Nakamura T. 1994. Cloning of the cDNA for a novel receptor tyrosine kinase, Sky, predominantly expressed in brain. Oncogene 9: 699-705.
115. Ohashi K, Nagata K, Toshima J, Nakano T, Arita H, Tsuda H, Suzuki K, Mizuno K. 1995. Stimulation of sky receptor tyrosine kinase by the product of growth arrest-specific gene 6. J Biol Chem 270: 22681-22684.
116. Ostergaard E, Duno M, Batbayli M, Vilhelmsen K, Rosenberg T. 2011. A novel MERTK deletion is a common founder mutation in the Faroe Islands and is responsible for a high proportion of retinitis pigmentosa cases. Mol Vis 17: 1485-1492.
117. Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ, Fletcher JA. 2011. AXL regulates mesothelioma proliferation and invasiveness. Oncogene 30: 1643-1652.
118. Pierce A, Bliesner B, Xu M, Nielsen-Preiss S, Lemke G, Tobet S, Wierman ME. 2008. Axl and Tyro3 modulate female reproduction by influencing gonadotropin-releasing hormone neuron survival and migration. Mol Endocrinol 22: 2481-2495.
119. Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, Delaney A, Wang Y, Bourbonais F, Lee DY, et al. 2012. Novel and selective spiroindoline-based inhibitors of Sky kinase. Bioorg Med Chem Lett 22: 190-193.
120. Prasad D, Rothlin CV, Burrola P, Burstyn-Cohen T, Lu Q, Garcia de Frutos P, Lemke G. 2006. TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci 33: 96-108.
121. Prieto AL, Weber JL, Lai C. 2000. Expression of the receptor protein-tyrosine kinases Tyro-3, Axl, and Mer in the developing rat central nervous system. J Comp Neurol 425: 295-314.
122. Prieto AL, O'Dell S, Varnum B, Lai C. 2007. Localization and signaling of the receptor protein tyrosine kinase Tyro3 in cortical and hippocampal neurons. Neuroscience 150: 319-334.
123. Quong RY, Bickford ST, Ing YL, Terman B, Herlyn M, Lassam NJ. 1994. Protein kinases in normal and transformed melanocytes. Melanoma Res 4: 313-319.
124. Radic MZ, Shah K, Lu Q, Lemke G, Hillard GM. 2006. Heterogeneous nuclear ribonucleoprotein P2 is an autoantibody target in mice deficient forMer, Axl, and Tyro3 receptor tyrosine kinases. J Immunology 176: 68-74.
125. Rajotte I, Hasanbasic I, Blostein M. 2008. Gas6-mediated signaling is dependent on the engagement of its gcarboxyglutamic acid domain with phosphatidylserine. Biochem Biophys Res Commun 376: 70-73.
126. Ravichandran KS. 2010. Find-me and eat-me signals in apoptotic cell clearance: Progress and conundrums. J Exp Med 207: 1807-1817.
127. Rescigno J, Mansukhani A, Basilico C. 1991. A putative receptor tyrosine kinase with unique structural topology. Oncogene 6: 1909-1913.
128. Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, Fey MF, Herrmann R, Neubauer A. 1999. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): Results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13: 1352-1358.
129. Ronnblom L, Pascual V. 2008. The innate immune system in SLE: Type I interferons and dendritic cells. Lupus 17: 394-399.
130. Rothlin CV, Lemke G. 2010. TAM receptor signaling and autoimmune disease. Curr Opin Immunol 22: 740-746.
131. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. 2007. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131: 1124-1136.
132. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. 2005. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 204: 36-44.
133. Sasaki T, Knyazev PG, Cheburkin Y, Gohring W, Tisi D, Ullrich A, Timpl R, Hohenester E. 2002. Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains. J Biol Chem 277: 44164-44170.
134. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, Timpl R, Hohenester E. 2006. Structural basis for Gas6-Axl signalling. EMBO J 25: 80-87.
135. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
136. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, Matsushima GK. 2001. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411: 207-211.
137. Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK. 2007. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunol 178: 5635-5642.
138. Shao WH, Cohen PL. 2011. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther 13: 202.
139. Shao WH, Zhen Y, Eisenberg RA, Cohen PL. 2009. TheMer receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses Gas6 as its ligand for uptake of apoptotic cells. Clin Immunol 133: 138-144.
140. Shao WH, Kuan AP, Wang C, Abraham V, Waldman MA, Vogelgesang A, Wittenburg G, Choudhury A, Tsao PY, Miwa T, et al. 2010. Disrupted Mer receptor tyrosine kinase expression leads to enhancedMZB-cell responses. J Autoimmun 35: 368-374.
141. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, Ivashkiv LB. 2006. Twist mediates suppression of inflammation by type I IFNs and Ax1. J Exp Med 203: 1891-1901.
142. Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T, Jones S, Feldmann H, Kawaoka Y. 2006. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol 80: 10109-10116.
143. Shimojima M, Ikeda Y, Kawaoka Y. 2007. The mechanism of Axl-mediated Ebola virus infection. J Infect Dis 196: S259-263.
144. Smiley ST, Boyer SN, Heeb MJ, Griffin JH, Grusby MJ. 1997. Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. Proc Natl Acad Sci 94: 11484-11489.
145. Soares MM, King SW, Thorpe PE. 2008. Targeting insideout phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 14: 1357-1362.
146. Son BK, Kozaki K, Iijima K, Eto M, Nakano T, Akishita M, Ouchi Y. 2007. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphateinduced calcification of vascular smooth muscle cells. Eur J Pharmacol 556: 1-8.
147. Song KS, Park YS, Kim HK. 2000. Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 43: 557-560.
148. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, Gomez HF, Evans DB. 2010. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117: 734-743.
149. Soriano P. 1997. The PDGF a receptor is required for neural crest cell development and for normal patterning of the somites. Development 124: 2691-2700.
150. Sparrow JR, Hicks D, Hamel CP. 2010. The retinal pigment epithelium in health and disease. Curr MolMed 10: 802-823.
151. Stafford DW. 2005. The vitamin K cycle. J Thromb Haemost 3: 1873-1878.
152. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF, et al. 1995. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80: 661-670.
153. Strick DJ, Feng W, Vollrath D. 2009. Mertk drives myosin II redistribution during retinal pigment epithelial phagocytosis. Invest Ophthalmol Vis Sci 50: 2427-2435.
154. Suh CH, Hilliard B, Li S, Merrill JT, Cohen PL. 2010. TAM receptor ligands in lupus: Protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther 12: R146.
155. Sun B, Qi N, Shang T, Wu H, Deng T, Han D. 2010. Sertoli cell-initiated testicular innate immune response through Toll-like receptor-3 activation is negatively regulated by Tyro3, Axl, andMer receptors. Endocrinology 151: 2886-2897.
156. Tanabe K, Nagata K, Ohashi K, Nakano T, Arita H, Mizuno K. 1997. Roles of g-carboxylation and a sex hormonebinding globulin-like domain in receptor-binding and in biological activities of Gas6. FEBS Lett 408: 306-310.
157. Thorp EB. 2010. Mechanisms of failed apoptotic cell clearance by phagocyte subsets in cardiovascular disease. Apoptosis 15: 1124-1136.
158. 2/2 mice. Arterioscler Thromb Vasc Biol 28: 1421-1428.
159. Tibrewal N, Wu Y, D'Mello V, Akakura R, George TC, Varnum B, Birge RB. 2008. Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-kB transcriptional activation. J Biol Chem 283: 3618-3627.
160. Todt JC, Hu B, Curtis JL. 2008. The scavenger receptor SR-A I/II (CD204) signals via the receptor tyrosine kinase Mertk during apoptotic cell uptake by murine macrophages. J Leukoc Biol 84: 510-518.
161. Uehara H, Shacter E. 2008. Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for Mer tyrosine kinase-mediated phagocytosis of apoptotic cells. J Immunol 180: 2522-2530.
162. van den Brand BT, Abdollahi-Roodsaz S, Vermeij EA, Bennink MB, Arntz OJ, Rothlin CV, van den Berg WB, van de Loo FA. 2013. Therapeutic efficacy of Tyro3, Axl, andMer tyrosine kinase agonists in collagen-induced arthritis. Arthritis Rheum 65: 671-680.
163. van Meer G, Voelker DR, Feigenson GW. 2008. Membrane lipids: Where they are and how they behave. Nat Rev Mol Cell Biol 9: 112-124.
164. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. 2011. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 10: 1763-1773.
165. Versteeg GA, Garcia-Sastre A. 2010. Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol 13: 508-516.
166. Wallet MA, Sen P, Flores RR, Wang Y, Yi Z, Huang Y, Mathews CE, Earp HS, Matsushima G, Wang B, et al. 2008. MerTK is required for apoptotic cell-induced T cell tolerance. J Exp Med 205: 219-232.
167. Weinger JG, Gohari P, Yan Y, Backer JM, Varnum B, Shafit-Zagardo B. 2008. In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; in vitro mutagenesis defines the requisite binding sites for downstream Akt activation. J Neurochem 106: 134-146.
168. Weinger JG, Brosnan CF, Loudig O, Goldberg MF, Macian F, Arnett HA, Prieto AL, Tsiperson V, Shafit-Zagardo B. 2011. Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis. J Neuroinflammation 8: 49.
169. Wu YM, Robinson DR, Kung HJ. 2004. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/ NYK in prostate cancer cells. Cancer Res 64: 7311-7320.
170. Wu Y, Tibrewal N, Birge RB. 2006. Phosphatidylserine recognition by phagocytes: Aview to a kill. Trends Cell Biol 16: 189-197.
171. Ye F, Han L, Lu Q, Dong W, Chen Z, Shao H, Kaplan HJ, Li Q. 2011. Retinal self-antigen induces a predominantly Th1 effector response in Axl andMertk double-knockout mice. J Immunol 187: 4178-4186.
172. Yoshimura A, Naka T, Kubo M. 2007. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7: 454-465.
173. Zezos P, Papaioannou G, Nikolaidis N, Vasiliadis T, Giouleme O, Evgenidis N. 2007. Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis. Hepatogastroenterology 54: 1417-1421.
174. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al. 2012. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44: 852-860.
175. Zhong Z, Wang Y, Guo H, Sagare A, Fernandez JA, Bell RD, Barrett TM, Griffin JH, Freeman RS, Zlokovic BV. 2010. Protein S protects neurons from excitotoxic injury by activating the TAMreceptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. J Neurosci 30: 15521-15534.
176. Zhu S, Wurdak H, Wang Y, Galkin A, Tao H, Li J, Lyssiotis CA, Yan F, Tu BP, Miraglia L, et al. 2009. A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci 106: 17025-17030.
177. Zhu D, Wang Y, Singh I, Bell RD, Deane R, Zhong Z, Sagare A, Winkler EA, Zlokovic BV. 2010. Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood 115: 4963-4972.
178. Zong C, Yan R, August A, Darnell JE Jr, Hanafusa H. 1996. Unique signal transduction of Eyk: Constitutive stimulation of the JAK-STAT pathway by an oncogenic receptortype tyrosine kinase. EMBO J 15: 4515-4525.